期刊
JOURNAL OF GENE MEDICINE
卷 16, 期 1-2, 页码 28-39出版社
WILEY
DOI: 10.1002/jgm.2755
关键词
gene transfer; microbubble; recombinant adeno-associated virus; renal cell carcinoma; ultrasound
资金
- Youth Foundation of Shanghai Health Bureau [2009Y034]
- National Natural Science Foundation of China (Youth Program) [81000687]
- National Natural Science Foundation of China [81171352, 81271596]
BackgroundRecombinant adeno-associated virus (rAAV) is recognized as a promising vector for cancer gene therapy, although its low transfer efficiency in less permissive cells limits extensive application. Our previous studies reported that ultrasound-targeted microbubble (MB) destruction (UTMD) enhanced rAAV transfer in its permissive retinal cells. In the present study, we investigated whether UTMD increased rAAV transfer in less permissive human renal cell carcinoma (hRCC) cells and tumors. MethodshRCC cells were treated with rAAV2 under different conditions of UTMD, and the viral transfer efficiency and cell viability were analyzed. Fifty-two male nude mice (BALB/c) implanted with hRCC cells were randomly assigned to four groups consisting of rAAV, rAAV+ultrasound and rAAV+UTMD (20 mu l and 40 mu l of MBs). UTMD was initiated immediately after intratumoral viral injection, and viral transfer efficiency and tumor volumes were analyzed at 12weeks after infection. ResultsThe efficiency of non-augmented transfer of rAAV2 into hRCC cells was low (17.282.44%). The use of UTMD enhanced viral transfer efficiency by two- to three-fold, and enhanced viral genomic DNA by more than nine-fold, without decreasing cell viability. In vivo studies also showed that UTMD increased rAAV2 transfer in tumor. The enhancements were maintained for a period of 12weeks. Tumor growth in mice was inhibited by UTMD treatment, and UTMD treatment augmented by MBs (40 mu l) produced an even stronger effect. ConclusionsUTMD enhanced rAAV2 transfer into less permissive RCC cells and tumors, resulting in inhibition of tumor growth, which suggests that UTMD may be a useful delivery tool for cancer gene therapy. Copyright (c) 2014 John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据